Significant changes are likely, but not fundamental overhaul.
The health care sector may face significant changes after the coming election cycle, particularly if a Democratic presidential candidate wins the general election.
Though several industries within health care face legislative and regulatory pressures, it’s unclear which specific industries a Democratic administration would prioritize for targeting reforms. However, we don’t expect the government under either party to try to lower the overall cost of health care.
Indeed, a fundamental overhaul to a single‑payer health care system is unlikely in a Democratic administration, in our view. As political party margins are not likely to shift meaningfully in the Senate, more radical reform proposals would not garner enough political will to pass. Instead, we should expect that a Democratic president would focus on lowering out‑of‑pocket health care costs Americans regularly experience, which will focus scrutiny on drug prices. The two leading Democratic candidates—former Vice President Joe Biden and Senator Bernie Sanders—support drug price limits or caps, particularly for drugs that manage chronic conditions like diabetes and HIV/AIDS.
If President Donald Trump is reelected, we would expect the federal government to pursue some forms of transparency and pricing regulations on drug manufacturers. The president, like Biden, favors a plan to move domestic drug prices toward an international index of prices.
“Medicare for All” Unlikely
Sanders’ Medicare for All plan would eliminate private health insurance and establish a single‑payer system that would guarantee every American government‑provided health care coverage. The plan would have no networks, premiums, deductibles, copays, or surprise bills. It would give the government more bargaining power in negotiating prices with drug manufacturers, hospitals, and physicians.
Because this plan would result in massive economic disruption, Medicare for All would take a tremendous amount of political support to pass—and a transition plan to stabilize the frictional unemployment that would occur. Given the recent strong Democratic primary performance of Biden, and the lack of political will in Congress, we believe such a significant change is not possible. In many districts, hospital systems are some of the largest employers; and the pharmaceutical lobby is one of the most powerful advocacy entities in the nation’s capital. We believe lawmakers will be hesitant to propose reforms that could jeopardize their odds of reelection.
Though Medicare for All isn’t likely within the next presidential term, we should expect the federal government, under either political party, to pursue some of its goals through regulatory action—like enhancing its negotiation power with drug manufacturers, broadening access to Medicare expansion, and creating more competitive pricing dynamics through generics.
More Likely: ACA Expansion. “Public Option” Possible, but Difficult
We should expect a Democratic president would fortify the Affordable Care Act (ACA) at a regulatory level and explore methods of extending access to Medicare coverage so that more uninsured and high‑risk patients gain access to insurance. We could also see plans akin to Biden’s “public option” proposal, in which the federal government would provide a publicly available insurance plan to directly compete with other managed care organizations. There are many Democratic senators across the ideological spectrum who are deeply invested in getting a public option across the finish line. But health care reform is notoriously difficult. The bill would have to receive bipartisan support in an increasingly partisan Congress.
The Coronavirus Impact
The growing presence of the COVID‑19 disease could also affect the political climate, as voters are being made aware in real time about their access to health care and the availability of treatment. The novel coronavirus has given the public another opportunity to consider how well our national health care system can respond to a crisis event, and many voters likely will conclude that our status quo is insufficient.
The outbreak also increases the political determination to pass legislation—or to at least consider substantial changes—to improve access to health care. Democrats running for office are expected to cite COVID‑19 as further evidence of the need for a more robust health care system, one in which the government plays a larger role in managing health care as a public good.
This material is being furnished for general informational and/or marketing purposes only. The material does not constitute or undertake to give advice of any nature, including fiduciary investment advice, nor is it intended to serve as the primary basis for an investment decision. Prospective investors are recommended to seek independent legal, financial and tax advice before making any investment decision. T. Rowe Price group of companies including T. Rowe Price Associates, Inc. and/or its affiliates receive revenue from T. Rowe Price investment products and services. Past performance is not a reliable indicator of future performance. The value of an investment and any income from it can go down as well as up. Investors may get back less than the amount invested.
The material does not constitute a distribution, an offer, an invitation, a personal or general recommendation or solicitation to sell or buy any securities in any jurisdiction or to conduct any particular investment activity. The material has not been reviewed by any regulatory authority in any jurisdiction.
Information and opinions presented have been obtained or derived from sources believed to be reliable and current; however, we cannot guarantee the sources’ accuracy or completeness. There is no guarantee that any forecasts made will come to pass. The views contained herein are as of the date written and are subject to change without notice; these views may differ from those of other T. Rowe Price group companies and/or associates. Under no circumstances should the material, in whole or in part, be copied or redistributed without consent from T. Rowe Price.
The material is not intended for use by persons in jurisdictions which prohibit or restrict the distribution of the material and in certain countries the material is provided upon specific request. It is not intended for distribution to retail investors in any jurisdiction.
Australia—Issued in Australia by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. For Wholesale Clients only.
Brunei—This material can only be delivered to certain specific institutional investors for informational purpose upon request only. The strategy and/or any products associated with the strategy has not been authorised for distribution in Brunei. No distribution of this material to any member of the public in Brunei is permitted.
Canada—Issued in Canada by T. Rowe Price (Canada), Inc. T. Rowe Price (Canada), Inc.’s investment management services are only available to Accredited Investors as defined under National Instrument 45-106. T. Rowe Price (Canada), Inc. enters into written delegation agreements with affiliates to provide investment management services.
China—This material is provided to specific qualified domestic institutional investor or sovereign wealth fund on a one-on-one basis. No invitation to offer, or offer for, or sale of, the shares will be made in the People’s Republic of China (“PRC”) (which, for such purpose, does not include the Hong Kong or Macau Special Administrative Regions or Taiwan) or by any means that would be deemed public under the laws of the PRC. The information relating to the strategy contained in this material has not been submitted to or approved by the China Securities Regulatory Commission or any other relevant governmental authority in the PRC. The strategy and/or any product associated with the strategy may only be offered or sold to investors in the PRC that are expressly authorized under the laws and regulations of the PRC to buy and sell securities denominated in a currency other than the Renminbi (or RMB), which is the official currency of the PRC. Potential investors who are resident in the PRC are responsible for obtaining the required approvals from all relevant government authorities in the PRC, including, but not limited to, the State Administration of Foreign Exchange, before purchasing the shares. This document further does not constitute any securities or investment advice to citizens of the PRC, or nationals with permanent residence in the PRC, or to any corporation, partnership, or other entity incorporated or established in the PRC.
DIFC—Issued in the Dubai International Financial Centre by T. Rowe Price International Ltd. This material is communicated on behalf of T. Rowe Price International Ltd. by its representative office which is regulated by the Dubai Financial Services Authority. For Professional Clients only.
EEA ex-UK—Unless indicated otherwise this material is issued and approved by T. Rowe Price (Luxembourg) Management S.à r.l. 35 Boulevard du Prince Henri L-1724 Luxembourg which is authorised and regulated by the Luxembourg Commission de Surveillance du Secteur Financier. For Professional Clients only.
Hong Kong—Issued in Hong Kong by T. Rowe Price Hong Kong Limited, 6/F, Chater House, 8 Connaught Road Central, Hong Kong. T. Rowe Price Hong Kong Limited is licensed and regulated by the Securities & Futures Commission. For Professional Investors only.
Indonesia—This material is intended to be used only by the designated recipient to whom T. Rowe Price delivered; it is for institutional use only. Under no circumstances should the material, in whole or in part, be copied, redistributed or shared, in any medium, without prior written consent from T. Rowe Price. No distribution of this material to members of the public in any jurisdiction is permitted.
Korea—This material is intended only to Qualified Professional Investors upon specific and unsolicited request and may not be reproduced in whole or in part nor can they be transmitted to any other person in the Republic of Korea.
Malaysia—This material can only be delivered to specific institutional investor upon specific and unsolicited request. The strategy and/or any products associated with the strategy has not been authorised for distribution in Malaysia. This material is solely for institutional use and for informational purposes only. This material does not provide investment advice or an offering to make, or an inducement or attempted inducement of any person to enter into or to offer to enter into, an agreement for or with a view to acquiring, disposing of, subscribing for or underwriting securities. Nothing in this material shall be considered a making available of, solicitation to buy, an offering for subscription or purchase or an invitation to subscribe for or purchase any securities, or any other product or service, to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the laws of Malaysia.
New Zealand—Issued in New Zealand by T. Rowe Price Australia Limited (ABN: 13 620 668 895 and AFSL: 503741), Level 50, Governor Phillip Tower, 1 Farrer Place, Suite 50B, Sydney, NSW 2000, Australia. No Interests are offered to the public. Accordingly, the Interests may not, directly or indirectly, be offered, sold or delivered in New Zealand, nor may any offering document or advertisement in relation to any offer of the Interests be distributed in New Zealand, other than in circumstances where there is no contravention of the Financial Markets Conduct Act 2013.
Philippines—THE STRATEGY AND/ OR ANY SECURITIES ASSOCIATED WITH THE STRATEGY BEING OFFERED OR SOLD HEREIN HAVE NOT BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION UNDER THE SECURITIES REGULATION CODE. ANY FUTURE OFFER OR SALE OF THE STRATEGY AND/ OR ANY SECURITIES IS SUBJECT TO REGISTRATION REQUIREMENTS UNDER THE CODE, UNLESS SUCH OFFER OR SALE QUALIFIES AS AN EXEMPT TRANSACTION.
Singapore—Issued in Singapore by T. Rowe Price Singapore Private Ltd., No. 501 Orchard Rd, #10-02 Wheelock Place, Singapore 238880. T. Rowe Price Singapore Private Ltd. is licensed and